 Anne Fuhlbrigge
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 98 | 2025 | 1920 | 9.580 |
Why?
| | Anti-Asthmatic Agents | 28 | 2025 | 273 | 3.370 |
Why?
| | Adrenal Cortex Hormones | 28 | 2025 | 501 | 3.340 |
Why?
| | Forced Expiratory Volume | 19 | 2019 | 489 | 1.560 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 11 | 2022 | 1050 | 1.360 |
Why?
| | Severity of Illness Index | 20 | 2020 | 2911 | 0.970 |
Why?
| | Administration, Inhalation | 25 | 2025 | 596 | 0.960 |
Why?
| | Anti-Inflammatory Agents | 10 | 2016 | 482 | 0.870 |
Why?
| | Albuterol | 5 | 2015 | 75 | 0.840 |
Why?
| | Bronchodilator Agents | 12 | 2016 | 198 | 0.830 |
Why?
| | Lung Transplantation | 10 | 2017 | 322 | 0.820 |
Why?
| | Budesonide | 14 | 2016 | 56 | 0.800 |
Why?
| | Remote Consultation | 4 | 2025 | 59 | 0.760 |
Why?
| | Nedocromil | 11 | 2016 | 23 | 0.720 |
Why?
| | Humans | 129 | 2025 | 141767 | 0.700 |
Why?
| | Nasal Polyps | 1 | 2021 | 61 | 0.690 |
Why?
| | Self Report | 3 | 2023 | 861 | 0.690 |
Why?
| | Endpoint Determination | 2 | 2020 | 78 | 0.680 |
Why?
| | Pharmacogenetics | 2 | 2015 | 168 | 0.670 |
Why?
| | Food Hypersensitivity | 1 | 2022 | 182 | 0.620 |
Why?
| | Sinusitis | 1 | 2021 | 239 | 0.590 |
Why?
| | Virus Diseases | 1 | 2021 | 215 | 0.580 |
Why?
| | Lung | 7 | 2019 | 4142 | 0.580 |
Why?
| | Glucocorticoids | 4 | 2022 | 534 | 0.570 |
Why?
| | Physicians | 2 | 2021 | 942 | 0.560 |
Why?
| | Symptom Assessment | 1 | 2019 | 130 | 0.550 |
Why?
| | Hospitalization | 13 | 2020 | 2264 | 0.550 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 317 | 0.520 |
Why?
| | Androstadienes | 3 | 2012 | 78 | 0.510 |
Why?
| | Bone Density | 2 | 2014 | 495 | 0.500 |
Why?
| | Child | 53 | 2022 | 22413 | 0.500 |
Why?
| | Disease Progression | 14 | 2020 | 2801 | 0.500 |
Why?
| | Oxygen Inhalation Therapy | 4 | 2020 | 184 | 0.490 |
Why?
| | Managed Care Programs | 8 | 2008 | 140 | 0.490 |
Why?
| | Male | 82 | 2025 | 70193 | 0.480 |
Why?
| | Emergency Service, Hospital | 9 | 2013 | 2193 | 0.480 |
Why?
| | Precision Medicine | 1 | 2020 | 434 | 0.470 |
Why?
| | Adult | 47 | 2025 | 39407 | 0.470 |
Why?
| | Female | 81 | 2025 | 75957 | 0.450 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 4 | 2020 | 27 | 0.450 |
Why?
| | Cost Savings | 1 | 2015 | 86 | 0.440 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 437 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 7 | 2020 | 1344 | 0.430 |
Why?
| | Peak Expiratory Flow Rate | 2 | 2011 | 25 | 0.410 |
Why?
| | Cost-Benefit Analysis | 7 | 2022 | 619 | 0.400 |
Why?
| | Middle Aged | 40 | 2025 | 34663 | 0.400 |
Why?
| | Phenotype | 6 | 2025 | 3178 | 0.390 |
Why?
| | Comorbidity | 4 | 2021 | 1664 | 0.360 |
Why?
| | Academic Medical Centers | 3 | 2024 | 531 | 0.350 |
Why?
| | Surveys and Questionnaires | 14 | 2022 | 5974 | 0.340 |
Why?
| | Adolescent | 37 | 2019 | 22138 | 0.340 |
Why?
| | Administration, Oral | 6 | 2021 | 803 | 0.330 |
Why?
| | Medical Records Systems, Computerized | 3 | 2008 | 96 | 0.330 |
Why?
| | Mentors | 1 | 2012 | 212 | 0.330 |
Why?
| | Quality of Life | 12 | 2023 | 3014 | 0.330 |
Why?
| | Respiratory Function Tests | 10 | 2015 | 568 | 0.320 |
Why?
| | United States | 23 | 2022 | 15310 | 0.320 |
Why?
| | Faculty, Medical | 1 | 2012 | 296 | 0.310 |
Why?
| | Interprofessional Relations | 3 | 2021 | 292 | 0.310 |
Why?
| | Child, Preschool | 31 | 2016 | 11512 | 0.300 |
Why?
| | Treatment Outcome | 16 | 2025 | 11182 | 0.300 |
Why?
| | Spirometry | 8 | 2020 | 264 | 0.300 |
Why?
| | Child Development | 1 | 2014 | 499 | 0.300 |
Why?
| | Group Practice | 1 | 2008 | 7 | 0.290 |
Why?
| | Anti-Allergic Agents | 2 | 2008 | 42 | 0.280 |
Why?
| | Oxygen | 3 | 2018 | 994 | 0.280 |
Why?
| | Aged | 22 | 2022 | 24754 | 0.280 |
Why?
| | Computer Simulation | 1 | 2012 | 1015 | 0.280 |
Why?
| | Dyspnea | 3 | 2022 | 258 | 0.260 |
Why?
| | Drug Utilization | 4 | 2005 | 169 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2020 | 1634 | 0.250 |
Why?
| | Primary Graft Dysfunction | 2 | 2017 | 34 | 0.240 |
Why?
| | Follow-Up Studies | 17 | 2017 | 5214 | 0.240 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 333 | 0.240 |
Why?
| | Primary Health Care | 5 | 2025 | 1809 | 0.240 |
Why?
| | Bronchiolitis Obliterans | 3 | 2017 | 65 | 0.240 |
Why?
| | Respiratory Sounds | 1 | 2006 | 109 | 0.230 |
Why?
| | Gift Giving | 1 | 2005 | 11 | 0.230 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2005 | 5 | 0.230 |
Why?
| | Allergists | 2 | 2022 | 11 | 0.230 |
Why?
| | Genetic Testing | 1 | 2008 | 463 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2021 | 962 | 0.220 |
Why?
| | Retrospective Studies | 18 | 2024 | 16375 | 0.210 |
Why?
| | Medication Adherence | 2 | 2023 | 513 | 0.210 |
Why?
| | Specialization | 2 | 2025 | 130 | 0.210 |
Why?
| | Cohort Studies | 14 | 2013 | 5815 | 0.210 |
Why?
| | Natural Language Processing | 1 | 2025 | 99 | 0.210 |
Why?
| | Time Factors | 10 | 2020 | 6967 | 0.210 |
Why?
| | Massachusetts | 5 | 2016 | 174 | 0.210 |
Why?
| | Leadership | 2 | 2022 | 399 | 0.210 |
Why?
| | Antibodies, Monoclonal | 2 | 2008 | 1474 | 0.200 |
Why?
| | Medicine | 1 | 2025 | 125 | 0.200 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2003 | 22 | 0.200 |
Why?
| | Genetic Variation | 1 | 2008 | 1000 | 0.200 |
Why?
| | Steroids | 8 | 2011 | 163 | 0.190 |
Why?
| | Recurrence | 5 | 2013 | 1112 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 2 | 2025 | 2375 | 0.190 |
Why?
| | Health Status | 1 | 2008 | 824 | 0.190 |
Why?
| | Predictive Value of Tests | 9 | 2012 | 2075 | 0.190 |
Why?
| | Beclomethasone | 1 | 2022 | 9 | 0.190 |
Why?
| | Multicenter Studies as Topic | 4 | 2018 | 363 | 0.190 |
Why?
| | Young Adult | 11 | 2019 | 13751 | 0.180 |
Why?
| | Prevalence | 4 | 2022 | 2799 | 0.180 |
Why?
| | Models, Theoretical | 4 | 2007 | 585 | 0.180 |
Why?
| | Tiotropium Bromide | 2 | 2018 | 5 | 0.180 |
Why?
| | Desensitization, Immunologic | 1 | 2022 | 95 | 0.180 |
Why?
| | Nebulizers and Vaporizers | 2 | 2020 | 68 | 0.180 |
Why?
| | Biomarkers | 3 | 2021 | 4191 | 0.170 |
Why?
| | Patient Preference | 1 | 2023 | 205 | 0.170 |
Why?
| | Social Class | 2 | 2022 | 268 | 0.170 |
Why?
| | Churg-Strauss Syndrome | 1 | 2020 | 27 | 0.160 |
Why?
| | Bronchoconstriction | 3 | 2011 | 31 | 0.160 |
Why?
| | Pulmonologists | 1 | 2020 | 14 | 0.160 |
Why?
| | Capacity Building | 1 | 2021 | 62 | 0.160 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 46 | 0.160 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 30 | 0.160 |
Why?
| | Agammaglobulinemia | 1 | 2020 | 36 | 0.160 |
Why?
| | Electronic Health Records | 2 | 2025 | 1132 | 0.160 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 585 | 0.160 |
Why?
| | Risk Factors | 12 | 2018 | 10483 | 0.160 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 1570 | 0.150 |
Why?
| | Air Pollution, Indoor | 2 | 2002 | 184 | 0.150 |
Why?
| | Treatment Adherence and Compliance | 1 | 2019 | 27 | 0.150 |
Why?
| | Exercise Test | 1 | 2022 | 625 | 0.150 |
Why?
| | Receptors, IgE | 2 | 2009 | 44 | 0.140 |
Why?
| | Prognosis | 8 | 2017 | 4084 | 0.140 |
Why?
| | Vitamin D | 2 | 2012 | 397 | 0.140 |
Why?
| | Allergens | 1 | 2021 | 401 | 0.140 |
Why?
| | Fossil Fuels | 1 | 1997 | 10 | 0.140 |
Why?
| | Alemtuzumab | 1 | 2017 | 15 | 0.130 |
Why?
| | Photopheresis | 1 | 2017 | 9 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 260 | 0.130 |
Why?
| | Drug Prescriptions | 2 | 2011 | 267 | 0.130 |
Why?
| | Biological Products | 1 | 2020 | 239 | 0.130 |
Why?
| | Emergency Medical Services | 2 | 2007 | 650 | 0.130 |
Why?
| | Respiration | 1 | 2017 | 210 | 0.130 |
Why?
| | Respiration Disorders | 1 | 1997 | 79 | 0.130 |
Why?
| | Physicians, Primary Care | 3 | 2021 | 226 | 0.130 |
Why?
| | Drug Combinations | 3 | 2012 | 368 | 0.120 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 434 | 0.120 |
Why?
| | Drug Therapy, Combination | 5 | 2020 | 1041 | 0.120 |
Why?
| | Immunomodulation | 1 | 2017 | 101 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2020 | 399 | 0.120 |
Why?
| | Breath Tests | 2 | 2008 | 77 | 0.120 |
Why?
| | Socioeconomic Factors | 4 | 2022 | 1317 | 0.120 |
Why?
| | Aged, 80 and over | 6 | 2019 | 7924 | 0.120 |
Why?
| | Scopolamine Derivatives | 1 | 2015 | 3 | 0.120 |
Why?
| | Tobacco Smoke Pollution | 2 | 2010 | 256 | 0.120 |
Why?
| | Patient Admission | 1 | 2018 | 203 | 0.120 |
Why?
| | Embolism, Fat | 1 | 2015 | 11 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2020 | 900 | 0.120 |
Why?
| | Cholinergic Antagonists | 1 | 2015 | 24 | 0.120 |
Why?
| | Transplants | 1 | 2015 | 38 | 0.120 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 99 | 0.120 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2012 | 8 | 0.120 |
Why?
| | Carcinoma, Bronchogenic | 1 | 2015 | 20 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2021 | 799 | 0.110 |
Why?
| | Genomics | 2 | 2018 | 815 | 0.110 |
Why?
| | Longitudinal Studies | 6 | 2017 | 2938 | 0.110 |
Why?
| | Overweight | 2 | 2011 | 588 | 0.110 |
Why?
| | Respiratory Tract Infections | 2 | 2012 | 385 | 0.110 |
Why?
| | Graft Rejection | 2 | 2013 | 547 | 0.110 |
Why?
| | Ambulatory Care Information Systems | 2 | 2005 | 5 | 0.110 |
Why?
| | Postoperative Complications | 2 | 2017 | 2821 | 0.110 |
Why?
| | Telemedicine | 1 | 2023 | 894 | 0.110 |
Why?
| | Prednisolone | 1 | 2014 | 69 | 0.110 |
Why?
| | Risk | 4 | 2015 | 907 | 0.100 |
Why?
| | Guideline Adherence | 3 | 2020 | 566 | 0.100 |
Why?
| | Education, Medical, Continuing | 2 | 2005 | 133 | 0.100 |
Why?
| | Airway Obstruction | 1 | 2015 | 165 | 0.100 |
Why?
| | Forecasting | 1 | 2015 | 384 | 0.100 |
Why?
| | Environmental Exposure | 3 | 2006 | 585 | 0.100 |
Why?
| | Bronchial Hyperreactivity | 3 | 2010 | 104 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 33 | 0.100 |
Why?
| | Quality Improvement | 1 | 2022 | 1254 | 0.100 |
Why?
| | Office Visits | 4 | 2011 | 95 | 0.100 |
Why?
| | Insurance Claim Review | 1 | 2013 | 85 | 0.100 |
Why?
| | Peer Group | 2 | 2012 | 247 | 0.100 |
Why?
| | Medicare | 2 | 2022 | 808 | 0.100 |
Why?
| | Growth | 1 | 2012 | 52 | 0.090 |
Why?
| | Double-Blind Method | 5 | 2010 | 1989 | 0.090 |
Why?
| | Cytomegalovirus Infections | 2 | 2012 | 197 | 0.090 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 222 | 0.090 |
Why?
| | Methacholine Chloride | 3 | 2008 | 50 | 0.090 |
Why?
| | Research | 1 | 2015 | 455 | 0.090 |
Why?
| | Metered Dose Inhalers | 1 | 2012 | 13 | 0.090 |
Why?
| | Cost of Illness | 3 | 2003 | 313 | 0.090 |
Why?
| | Drug Dosage Calculations | 1 | 2011 | 23 | 0.090 |
Why?
| | Feedback | 1 | 2012 | 179 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2008 | 913 | 0.090 |
Why?
| | Logistic Models | 5 | 2017 | 2092 | 0.090 |
Why?
| | Mycoses | 1 | 2012 | 86 | 0.090 |
Why?
| | Antifungal Agents | 1 | 2012 | 144 | 0.090 |
Why?
| | Body Height | 1 | 2012 | 200 | 0.090 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2011 | 9 | 0.090 |
Why?
| | Multivariate Analysis | 7 | 2017 | 1498 | 0.090 |
Why?
| | Professional Role | 1 | 2012 | 168 | 0.090 |
Why?
| | Medication Errors | 1 | 2012 | 97 | 0.090 |
Why?
| | Morbidity | 2 | 2022 | 322 | 0.090 |
Why?
| | Mycobacterium | 1 | 2012 | 112 | 0.080 |
Why?
| | Epidemiologic Studies | 1 | 2011 | 70 | 0.080 |
Why?
| | Obesity | 3 | 2015 | 3008 | 0.080 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 139 | 0.080 |
Why?
| | Patient Readmission | 1 | 2016 | 708 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2012 | 178 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2012 | 241 | 0.080 |
Why?
| | Program Development | 1 | 2012 | 368 | 0.080 |
Why?
| | Drug Resistance | 1 | 2011 | 150 | 0.080 |
Why?
| | Probability | 1 | 2011 | 309 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 190 | 0.080 |
Why?
| | Lung Diseases | 1 | 2017 | 794 | 0.080 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 521 | 0.080 |
Why?
| | Bronchial Provocation Tests | 2 | 2008 | 51 | 0.080 |
Why?
| | Fluticasone | 2 | 2008 | 56 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2012 | 431 | 0.080 |
Why?
| | Pragmatic Clinical Trials as Topic | 2 | 2020 | 127 | 0.080 |
Why?
| | Incidence | 5 | 2020 | 2806 | 0.080 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2009 | 28 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2008 | 331 | 0.080 |
Why?
| | Vital Capacity | 4 | 2017 | 312 | 0.080 |
Why?
| | Lectins, C-Type | 1 | 2009 | 63 | 0.080 |
Why?
| | Ambulatory Care | 2 | 2011 | 587 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1769 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1268 | 0.080 |
Why?
| | Health Services | 2 | 2007 | 118 | 0.070 |
Why?
| | Odds Ratio | 4 | 2017 | 1057 | 0.070 |
Why?
| | Medication Therapy Management | 1 | 2010 | 79 | 0.070 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 321 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2012 | 1406 | 0.070 |
Why?
| | Pandemics | 3 | 2022 | 1656 | 0.070 |
Why?
| | Acute Disease | 1 | 2011 | 1010 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 910 | 0.070 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2008 | 11 | 0.070 |
Why?
| | Smoking | 3 | 2017 | 1604 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 19 | 0.070 |
Why?
| | Cross-Sectional Studies | 6 | 2010 | 5697 | 0.070 |
Why?
| | Eosinophil Cationic Protein | 1 | 2008 | 9 | 0.070 |
Why?
| | Mixed Function Oxygenases | 1 | 2008 | 48 | 0.070 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 47 | 0.070 |
Why?
| | Program Evaluation | 1 | 2012 | 930 | 0.070 |
Why?
| | Adrenergic beta-Agonists | 1 | 2008 | 98 | 0.070 |
Why?
| | Genetic Techniques | 1 | 2008 | 67 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 2 | 2006 | 113 | 0.070 |
Why?
| | Trastuzumab | 1 | 2008 | 97 | 0.070 |
Why?
| | Markov Chains | 2 | 2006 | 126 | 0.070 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2008 | 24 | 0.070 |
Why?
| | Cost Sharing | 1 | 2008 | 19 | 0.070 |
Why?
| | State Health Plans | 1 | 2008 | 34 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2012 | 440 | 0.070 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2007 | 52 | 0.070 |
Why?
| | Reimbursement Mechanisms | 1 | 2008 | 83 | 0.070 |
Why?
| | Omalizumab | 1 | 2007 | 40 | 0.070 |
Why?
| | Chronic Disease | 3 | 2017 | 1822 | 0.070 |
Why?
| | Exercise Tolerance | 2 | 2022 | 280 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 364 | 0.070 |
Why?
| | Warfarin | 1 | 2008 | 153 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2011 | 854 | 0.070 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 296 | 0.070 |
Why?
| | Health Surveys | 2 | 2006 | 513 | 0.070 |
Why?
| | Antiviral Agents | 1 | 2012 | 747 | 0.060 |
Why?
| | Influenza Vaccines | 1 | 2012 | 551 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1448 | 0.060 |
Why?
| | Animals, Domestic | 1 | 2006 | 16 | 0.060 |
Why?
| | Health Services Accessibility | 2 | 2021 | 1027 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2765 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2013 | 655 | 0.060 |
Why?
| | Animals | 2 | 2025 | 37748 | 0.060 |
Why?
| | Physicians, Family | 2 | 2004 | 195 | 0.060 |
Why?
| | Eosinophils | 1 | 2008 | 326 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 708 | 0.060 |
Why?
| | Health Benefit Plans, Employee | 1 | 2005 | 27 | 0.060 |
Why?
| | Database Management Systems | 1 | 2005 | 51 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1828 | 0.060 |
Why?
| | Hip Fractures | 1 | 2006 | 86 | 0.060 |
Why?
| | Patients | 1 | 2006 | 180 | 0.060 |
Why?
| | Health Policy | 1 | 2008 | 405 | 0.060 |
Why?
| | Insurance Coverage | 1 | 2006 | 239 | 0.060 |
Why?
| | Utilization Review | 1 | 2004 | 41 | 0.050 |
Why?
| | Infant | 3 | 2008 | 9843 | 0.050 |
Why?
| | Patient Education as Topic | 3 | 2005 | 778 | 0.050 |
Why?
| | Body Mass Index | 3 | 2015 | 2385 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1771 | 0.050 |
Why?
| | Clinical Competence | 1 | 2012 | 1205 | 0.050 |
Why?
| | Medicaid | 1 | 2008 | 451 | 0.050 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2010 | 663 | 0.050 |
Why?
| | Anticoagulants | 1 | 2008 | 675 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1313 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2008 | 900 | 0.050 |
Why?
| | Sex Factors | 3 | 2016 | 2063 | 0.050 |
Why?
| | Attitude to Health | 1 | 2006 | 458 | 0.050 |
Why?
| | Vaccination | 1 | 2012 | 1472 | 0.050 |
Why?
| | Case Management | 1 | 2003 | 67 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2005 | 1057 | 0.050 |
Why?
| | Puerto Rico | 1 | 2022 | 54 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2004 | 1866 | 0.050 |
Why?
| | Choice Behavior | 1 | 2004 | 172 | 0.050 |
Why?
| | Parents | 3 | 2006 | 1440 | 0.050 |
Why?
| | Symptom Flare Up | 1 | 2022 | 38 | 0.050 |
Why?
| | Sputum | 1 | 2004 | 313 | 0.050 |
Why?
| | Academies and Institutes | 1 | 2022 | 55 | 0.050 |
Why?
| | Circadian Rhythm | 1 | 2006 | 515 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2567 | 0.040 |
Why?
| | Health Services Research | 1 | 2004 | 406 | 0.040 |
Why?
| | Minority Groups | 1 | 2003 | 278 | 0.040 |
Why?
| | Survival Rate | 2 | 2016 | 1972 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2020 | 76 | 0.040 |
Why?
| | Electronics | 1 | 2021 | 72 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 111 | 0.040 |
Why?
| | Efficiency | 1 | 2021 | 101 | 0.040 |
Why?
| | Sample Size | 1 | 2020 | 128 | 0.040 |
Why?
| | Health Care Reform | 1 | 2021 | 112 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 152 | 0.040 |
Why?
| | Risk Assessment | 3 | 2020 | 3508 | 0.040 |
Why?
| | Patient Selection | 2 | 2020 | 688 | 0.040 |
Why?
| | Language | 1 | 2022 | 309 | 0.040 |
Why?
| | Patient Compliance | 2 | 2016 | 611 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2007 | 1133 | 0.040 |
Why?
| | Time | 1 | 2019 | 87 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2014 | 521 | 0.040 |
Why?
| | Health Education | 1 | 2002 | 364 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2003 | 658 | 0.040 |
Why?
| | Poland | 1 | 2017 | 35 | 0.030 |
Why?
| | Republic of Korea | 1 | 2017 | 41 | 0.030 |
Why?
| | Bronchitis, Chronic | 1 | 2017 | 26 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2021 | 463 | 0.030 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1978 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2003 | 550 | 0.030 |
Why?
| | Nitrogen Dioxide | 1 | 1997 | 45 | 0.030 |
Why?
| | Geography | 1 | 2018 | 201 | 0.030 |
Why?
| | Long-Term Care | 1 | 2018 | 110 | 0.030 |
Why?
| | Aftercare | 1 | 2019 | 218 | 0.030 |
Why?
| | Monitoring, Physiologic | 2 | 2012 | 285 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 87 | 0.030 |
Why?
| | Self Concept | 1 | 2019 | 262 | 0.030 |
Why?
| | Pediatrics | 1 | 2005 | 1100 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 2169 | 0.030 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2017 | 142 | 0.030 |
Why?
| | Formoterol Fumarate | 1 | 2015 | 7 | 0.030 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2015 | 12 | 0.030 |
Why?
| | Salmeterol Xinafoate | 1 | 2015 | 22 | 0.030 |
Why?
| | Perception | 1 | 2019 | 378 | 0.030 |
Why?
| | Ethanolamines | 1 | 2015 | 15 | 0.030 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2015 | 33 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 355 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1027 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2064 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2135 | 0.030 |
Why?
| | Education | 1 | 2015 | 109 | 0.030 |
Why?
| | Self Efficacy | 1 | 2019 | 408 | 0.030 |
Why?
| | Postoperative Period | 1 | 2016 | 361 | 0.030 |
Why?
| | Age Factors | 3 | 2008 | 3294 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2015 | 309 | 0.030 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 855 | 0.030 |
Why?
| | Biopsy | 2 | 2013 | 1083 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1826 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1249 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 881 | 0.030 |
Why?
| | Gene Expression | 1 | 2018 | 1492 | 0.030 |
Why?
| | Echinocandins | 1 | 2012 | 8 | 0.020 |
Why?
| | Telephone | 2 | 2005 | 182 | 0.020 |
Why?
| | Lipopeptides | 1 | 2012 | 14 | 0.020 |
Why?
| | Aspergillosis | 1 | 2012 | 22 | 0.020 |
Why?
| | Amphotericin B | 1 | 2012 | 36 | 0.020 |
Why?
| | Intention to Treat Analysis | 1 | 2012 | 76 | 0.020 |
Why?
| | Tissue Donors | 1 | 2015 | 406 | 0.020 |
Why?
| | Candidiasis | 1 | 2012 | 63 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 415 | 0.020 |
Why?
| | Mycobacterium avium Complex | 1 | 2012 | 87 | 0.020 |
Why?
| | Age Distribution | 2 | 2003 | 397 | 0.020 |
Why?
| | Hypoxia | 1 | 2019 | 1165 | 0.020 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2015 | 345 | 0.020 |
Why?
| | Cromolyn Sodium | 2 | 2001 | 5 | 0.020 |
Why?
| | Leukotriene Antagonists | 1 | 2011 | 24 | 0.020 |
Why?
| | Triazoles | 1 | 2012 | 162 | 0.020 |
Why?
| | Functional Residual Capacity | 1 | 2010 | 7 | 0.020 |
Why?
| | Self Care | 2 | 2005 | 395 | 0.020 |
Why?
| | Reference Values | 1 | 2012 | 808 | 0.020 |
Why?
| | Costa Rica | 1 | 2010 | 18 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4629 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2011 | 198 | 0.020 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2012 | 205 | 0.020 |
Why?
| | Health | 1 | 2010 | 84 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1406 | 0.020 |
Why?
| | Inhalation | 1 | 2010 | 29 | 0.020 |
Why?
| | Environment | 1 | 2011 | 342 | 0.020 |
Why?
| | Observation | 1 | 2008 | 56 | 0.020 |
Why?
| | Sex Ratio | 1 | 2008 | 15 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2008 | 78 | 0.020 |
Why?
| | Models, Econometric | 1 | 2008 | 36 | 0.020 |
Why?
| | Prospective Studies | 2 | 2012 | 7777 | 0.020 |
Why?
| | Health Services Administration | 1 | 2007 | 8 | 0.020 |
Why?
| | Treatment Refusal | 1 | 2008 | 96 | 0.020 |
Why?
| | Social Isolation | 1 | 2007 | 66 | 0.020 |
Why?
| | Intelligence | 1 | 2007 | 134 | 0.020 |
Why?
| | Puberty | 1 | 2008 | 152 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 997 | 0.020 |
Why?
| | Child Behavior Disorders | 1 | 2007 | 143 | 0.020 |
Why?
| | Exercise | 1 | 2016 | 2112 | 0.010 |
Why?
| | Insurance, Health | 1 | 2007 | 299 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2011 | 1115 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1866 | 0.010 |
Why?
| | Bronchoconstrictor Agents | 1 | 2003 | 14 | 0.010 |
Why?
| | Organizational Innovation | 1 | 2004 | 138 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2004 | 163 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2010 | 3597 | 0.010 |
Why?
| | Systems Integration | 1 | 2003 | 38 | 0.010 |
Why?
| | Computer Systems | 1 | 2003 | 51 | 0.010 |
Why?
| | Motor Activity | 1 | 2007 | 720 | 0.010 |
Why?
| | Self Disclosure | 1 | 2002 | 65 | 0.010 |
Why?
| | Histamine H1 Antagonists | 1 | 2002 | 28 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 771 | 0.010 |
Why?
| | Child Welfare | 1 | 2004 | 229 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2002 | 92 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2002 | 329 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 1023 | 0.010 |
Why?
| | Nurse's Role | 1 | 2003 | 167 | 0.010 |
Why?
| | Point-of-Care Systems | 1 | 2003 | 188 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2002 | 566 | 0.010 |
Why?
| | Sex Distribution | 1 | 2001 | 381 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2004 | 697 | 0.010 |
Why?
| | Linear Models | 1 | 2002 | 858 | 0.010 |
Why?
| | Disease Management | 1 | 2003 | 633 | 0.010 |
Why?
| | Decision Support Systems, Clinical | 1 | 2003 | 263 | 0.010 |
Why?
| | Caregivers | 1 | 2007 | 943 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2000 | 226 | 0.010 |
Why?
| | Internet | 1 | 2003 | 690 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 7092 | 0.010 |
Why?
| | Survival Analysis | 1 | 2000 | 1320 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2004 | 6289 | 0.010 |
Why?
|
|
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|